WHO Issues Concern Over Acute Lack of Obesity Injections
Less than one in 10 individuals eligible to benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it releases its first guidance on the drugs.
With more than one billion individuals worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major obstacles to widespread availability to the injections that can help people shift considerable body mass, says the agency.
GLP-1 Therapy Scarcity
Even in the current best projected scenario, the production of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the health organization.
The guideline urges nations and manufacturers to expand availability, via approaches including voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in several countries in 2026.
How Weight-Loss Drugs Work
These medications mimick a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so individuals eat less.
Individuals commonly begin shedding pounds within a few weeks of starting on the weekly injections.
Research suggests people may regain a significant portion a year later of stopping the drug, because their normal hunger return.
To be carrying excess weight raises your chance for experiencing diseases, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight affects individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, per the health agency.
